Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.73 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.62 |
| ▸ | USP1 | O94782 | 1/20 | 0.58 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.58 |
| ▸ | NCF1 | P14598 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3120955 | 0.99 | APP (0.72) | APPSLC2A1POLBEGFRNR2F2 | |
| Sulfuric Acid SCHEMBL3125331 | 0.93 | APP (0.65) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL3106193 | 0.90 | APP (0.70) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL3110568 | 0.89 | APP (0.71) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL3116114 | 0.88 | APP (0.57) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL92716 | 0.88 | APP (0.70) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL3110583 | 0.88 | APP (0.70) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL3115914 | 0.88 | APP (0.70) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL3119160 | 0.88 | APP (0.70) | APPSLC2A1POLBEGFRNR2F2 | |
| SCHEMBL4864671 | 0.88 | APP (0.70) | APPSLC2A1POLBEGFRNR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011527693-A | — | — | 2011-11-04 | — | — | JP | claimed |
| US-20110224240-A1 | METHODS OF TREATING CANCER AND RELATED DISEASES | MYREXIS, INC. (US) | 2011-09-15 | — | — | US | claimed |
| US-20110200619-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF | MYREXIS, INC. (US) | 2011-08-18 | — | — | US | claimed |
| EP-2309856-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND THE USE THEREOF | Myrexis, Inc. (US) | 2011-04-20 | — | — | EP | claimed |
| WO-2010006115-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND THE USE THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | claimed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110224240-A1 | METHODS OF TREATING CANCER AND RELATED DISEASES | MYREXIS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110200619-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF | MYREXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2309856-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND THE USE THEREOF | Myrexis, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068197-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010006115-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND THE USE THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | APP 2989/4885SLC2A1 2605/4885POLB 1857/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | APP 3261/4885SLC2A1 2886/4885POLB 1789/4885 |
| US-20110224240-A1 | METHODS OF TREATING CANCER AND RELATED DISEASES | VHL, GLS2, SLC19A1 | APP 4679/4885SLC2A1 9/4885POLB 1020/4885 |
| US-20110200619-A1 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF | TP53, NFATC1, BAD | APP 4331/4885SLC2A1 861/4885POLB 1433/4885 |
| US-20100068197-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MKI67, CCNI, CCNA1 | APP 3879/4885SLC2A1 337/4885POLB 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.